SALE EXTENDED
MarketBeat All Access
Start your 30-day free trial,
then continue your subscription for 50% off.
TODAY ONLY!
Claim Your Discount
×
S&P 500   3,679.35 (-1.74%)
DOW   29,539.03 (-1.30%)
QQQ   272.16 (-2.72%)
AAPL   141.18 (-2.92%)
MSFT   235.75 (-4.47%)
META   135.36 (-2.67%)
GOOGL   99.47 (-1.92%)
AMZN   116.06 (-3.52%)
TSLA   228.81 (-3.91%)
NVDA   124.84 (-4.92%)
NIO   13.85 (-6.23%)
BABA   82.14 (-2.59%)
AMD   61.96 (-8.68%)
T   15.06 (-1.70%)
MU   53.18 (-2.64%)
CGC   3.18 (-15.20%)
F   12.18 (-1.46%)
GE   64.97 (-1.89%)
DIS   97.63 (-2.41%)
AMC   6.75 (-5.20%)
PYPL   91.87 (-2.70%)
PFE   42.48 (-1.42%)
NFLX   232.55 (-3.11%)
S&P 500   3,679.35 (-1.74%)
DOW   29,539.03 (-1.30%)
QQQ   272.16 (-2.72%)
AAPL   141.18 (-2.92%)
MSFT   235.75 (-4.47%)
META   135.36 (-2.67%)
GOOGL   99.47 (-1.92%)
AMZN   116.06 (-3.52%)
TSLA   228.81 (-3.91%)
NVDA   124.84 (-4.92%)
NIO   13.85 (-6.23%)
BABA   82.14 (-2.59%)
AMD   61.96 (-8.68%)
T   15.06 (-1.70%)
MU   53.18 (-2.64%)
CGC   3.18 (-15.20%)
F   12.18 (-1.46%)
GE   64.97 (-1.89%)
DIS   97.63 (-2.41%)
AMC   6.75 (-5.20%)
PYPL   91.87 (-2.70%)
PFE   42.48 (-1.42%)
NFLX   232.55 (-3.11%)
S&P 500   3,679.35 (-1.74%)
DOW   29,539.03 (-1.30%)
QQQ   272.16 (-2.72%)
AAPL   141.18 (-2.92%)
MSFT   235.75 (-4.47%)
META   135.36 (-2.67%)
GOOGL   99.47 (-1.92%)
AMZN   116.06 (-3.52%)
TSLA   228.81 (-3.91%)
NVDA   124.84 (-4.92%)
NIO   13.85 (-6.23%)
BABA   82.14 (-2.59%)
AMD   61.96 (-8.68%)
T   15.06 (-1.70%)
MU   53.18 (-2.64%)
CGC   3.18 (-15.20%)
F   12.18 (-1.46%)
GE   64.97 (-1.89%)
DIS   97.63 (-2.41%)
AMC   6.75 (-5.20%)
PYPL   91.87 (-2.70%)
PFE   42.48 (-1.42%)
NFLX   232.55 (-3.11%)
S&P 500   3,679.35 (-1.74%)
DOW   29,539.03 (-1.30%)
QQQ   272.16 (-2.72%)
AAPL   141.18 (-2.92%)
MSFT   235.75 (-4.47%)
META   135.36 (-2.67%)
GOOGL   99.47 (-1.92%)
AMZN   116.06 (-3.52%)
TSLA   228.81 (-3.91%)
NVDA   124.84 (-4.92%)
NIO   13.85 (-6.23%)
BABA   82.14 (-2.59%)
AMD   61.96 (-8.68%)
T   15.06 (-1.70%)
MU   53.18 (-2.64%)
CGC   3.18 (-15.20%)
F   12.18 (-1.46%)
GE   64.97 (-1.89%)
DIS   97.63 (-2.41%)
AMC   6.75 (-5.20%)
PYPL   91.87 (-2.70%)
PFE   42.48 (-1.42%)
NFLX   232.55 (-3.11%)
NASDAQ:VXRT

Vaxart - VXRT Stock Forecast, Price & News

$1.93
-0.06 (-3.02%)
(As of 10/7/2022 10:40 AM ET)
Add
Compare
Today's Range
$1.91
$1.96
50-Day Range
$1.99
$4.46
52-Week Range
$1.97
$8.13
Volume
38,963 shs
Average Volume
2.91 million shs
Market Capitalization
$244.16 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$10.67

Vaxart MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.75 Rating Score
Upside/​Downside
458.5% Upside
$10.67 Price Target
Short Interest
Bearish
18.97% of Shares Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
-0.37mentions of Vaxart in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Decreasing
From ($0.84) to ($0.93) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.40 out of 5 stars

Medical Sector

1028th out of 1,075 stocks

Biological Products, Except Diagnostic Industry

164th out of 170 stocks

VXRT stock logo

About Vaxart (NASDAQ:VXRT) Stock

Vaxart, Inc., a clinical-stage biotechnology company, engages in the discovery and development of oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, an oral tablet vaccine, which is in a Phase Ib clinical trial with bivalent oral tablet vaccine for the GI.1 and GII.4 norovirus strains; seasonal influenza vaccine, which is in Phase II clinical trial for the treatment of H1 influenza infection; respiratory syncytial virus vaccine; and coronavirus vaccine, which is in Phase II clinical trial for the treatment of SARS-CoV-2 infection. It is also developing therapeutic vaccines for cervical cancer and dysplasia caused by human papillomavirus. The company is headquartered in South San Francisco, California.

Receive VXRT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaxart and its competitors with MarketBeat's FREE daily newsletter.

VXRT Stock News Headlines

The $193 Billion US-China War You Don't Know About
They're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.
The $193 Billion US-China War You Don't Know About
They're fighting for control of lithium – a key ingredient in EVs and clean energy technology. It's arguably the most important commodity of the 21st century. China owns 80% of global supply. But the US plans to grab a massive slice of the lithium market, which is forecasted to quadruple to $193 billion by 2028, according to Fortune Business Insights.
What Is Going on With Vaxart (VXRT) Stock Today?
See More Headlines
Receive VXRT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Vaxart and its competitors with MarketBeat's FREE daily newsletter.

VXRT Company Calendar

Last Earnings
8/08/2022
Today
10/07/2022
Next Earnings (Estimated)
11/03/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VXRT
Previous Symbol
NASDAQ:NABI
Employees
110
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$10.67
High Stock Price Forecast
$18.00
Low Stock Price Forecast
$6.00
Forecasted Upside/Downside
+452.7%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.75
Research Coverage
4 Analysts

Profitability

Net Income
$-70,470,000.00
Net Margins
-16,892.57%
Pretax Margin
-25,850.70%

Debt

Sales & Book Value

Annual Sales
$890,000.00
Book Value
$1.49 per share

Miscellaneous

Free Float
122,964,000
Market Cap
$244.16 million
Optionable
Not Optionable
Beta
0.95

Key Executives

  • Mr. Cezar Andrei Floroiu M.B.A. (Age 49)
    CEO, Pres & Director
    Comp: $674.23k
  • Dr. Sean N. TuckerDr. Sean N. Tucker (Age 54)
    Sr. VP & Chief Scientific Officer
    Comp: $494.77k
  • Dr. James F. Cummings M.D. (Age 56)
    Chief Medical Officer
    Comp: $151.95k
  • Mr. Fuad Ahmad (Age 52)
    Interim CFO and Principal Financial & Accounting Officer
  • Mr. Edward B. Berg (Age 58)
    Sr. VP & Gen. Counsel
  • Ms. Shaily Jaini Garg
    Sr. VP of Clinical Devel. & Project Management
  • Mr. Brant Biehn
    Sr. VP of Bus. Operations
  • Dr. Rajesh Kapoor Ph.D.
    Sr. VP of Quality
  • Mr. John M. Harland M.B.A. (Age 70)
    CPA, Consultant













VXRT Stock - Frequently Asked Questions

Should I buy or sell Vaxart stock right now?

4 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Vaxart in the last year. There are currently 1 hold rating and 3 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" VXRT shares.
View VXRT analyst ratings
or view top-rated stocks.

What is Vaxart's stock price forecast for 2022?

4 Wall Street research analysts have issued 1-year price objectives for Vaxart's shares. Their VXRT share price forecasts range from $6.00 to $18.00. On average, they predict the company's share price to reach $10.67 in the next year. This suggests a possible upside of 436.0% from the stock's current price.
View analysts price targets for VXRT
or view top-rated stocks among Wall Street analysts.

How have VXRT shares performed in 2022?

Vaxart's stock was trading at $6.27 on January 1st, 2022. Since then, VXRT stock has decreased by 68.3% and is now trading at $1.99.
View the best growth stocks for 2022 here
.

When is Vaxart's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, November 3rd 2022.
View our VXRT earnings forecast
.

How were Vaxart's earnings last quarter?

Vaxart, Inc. (NASDAQ:VXRT) announced its quarterly earnings results on Monday, August, 8th. The biotechnology company reported ($0.23) EPS for the quarter, missing the consensus estimate of ($0.21) by $0.02. Vaxart had a negative net margin of 16,892.57% and a negative trailing twelve-month return on equity of 52.93%. During the same quarter in the prior year, the firm earned ($0.13) earnings per share.

When did Vaxart's stock split?

Vaxart's stock reverse split on the morning of Wednesday, February 14th 2018. The 1-11 reverse split was announced on Tuesday, February 13th 2018. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, February 13th 2018. An investor that had 100 shares of stock prior to the reverse split would have 9 shares after the split.

What other stocks do shareholders of Vaxart own?
What is Vaxart's stock symbol?

Vaxart trades on the NASDAQ under the ticker symbol "VXRT."

Who are Vaxart's major shareholders?

Vaxart's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Beacon Capital Management LLC (0.01%). Insiders that own company stock include Armistice Capital Master Fund, Armistice Capital, Llc, Fuad Ahmad, John P Richard, Margaret Echerd, Robert A Yedid, Sean Tucker, Todd C Davis and Wouter Latour.
View institutional ownership trends
.

How do I buy shares of Vaxart?

Shares of VXRT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Vaxart's stock price today?

One share of VXRT stock can currently be purchased for approximately $1.99.

How much money does Vaxart make?

Vaxart (NASDAQ:VXRT) has a market capitalization of $251.75 million and generates $890,000.00 in revenue each year. The biotechnology company earns $-70,470,000.00 in net income (profit) each year or ($0.74) on an earnings per share basis.

How many employees does Vaxart have?

The company employs 110 workers across the globe.

How can I contact Vaxart?

Vaxart's mailing address is 290 Utah Ave. Suite 200, South San Francisco CA, 94080. The official website for the company is www.vaxart.com. The biotechnology company can be reached via phone at (650) 550-3500, via email at ir@vaxart.com, or via fax at 650-871-8580.

This page (NASDAQ:VXRT) was last updated on 10/7/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access members have access to premium reports, best-in-class portfolio monitoring tools, and our latest stock picks.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies, and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.